Abstract:Abstract Mutations in mitochondrial genes are primary causes of multiple inherited disorders, especially affecting tissues with high aerobic energy demands such as the eye, brain, heart, and skeletal muscles. Such mitochondrial diseases are untreatable, have poor prognoses, and relevant animal models are few. Here we microinjected into the mouse blastocyst an adeno-associated virus (AAV) that we redirected to mitochondria to deliver the mutant human adenosine triphosphate (ATP) synthase subunit 6 gene (m.8993T>G) responsible for Maternally Inherited Leigh Syndrome, a neurologic disease renowned for causing rapidly fatal encephalomyelopathy in childhood or Neuropathy, Ataxia and Retinitis Pigmentosa in adults. Mice bred over six generations exhibited hallmarks of the human disease with one or multiple systemic symptoms including early death, paralysis, hunching, vision loss and seizures. Necropsy revealed spongiform encephalopathy, retinal degeneration, and cardiomegaly. Intravenous injection of a mitochondrially directed AAV serotype 9 vector containing wild-type ATP6 after disease onset, conferred prolonged survival and reduced paralysis. When administered prior to disease onset, all treated mice survived, and visual and motor function improved. These results support further development of gene therapy strategies involving intravenous delivery of mito-targeted AAV9.

Amelioration of Leigh syndrome induced by mouse blastocyst complementation with a mutant human mitochondrial ATP synthase 6